These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 6576728)

  • 1. Modifying the biological response to acute myeloid leukemia I. BCG, allogeneic leukemic cells and spontaneous cytotoxicity.
    Arends-Merino A; Sjögren AM; Reizenstein P
    Anticancer Res; 1983; 3(4):239-41. PubMed ID: 6576728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmentation of human natural killer cell activity by cyclophosphamide in vitro.
    Sharma B; Vaziri ND
    Cancer Res; 1984 Aug; 44(8):3258-61. PubMed ID: 6589041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporine-induced autologous graft-versus-host disease in patients with acute myeloid leukemia undergoing non-myeloablative chemotherapy without progenitor cell reinfusion.
    Stein M; Feldman E; Seiter K; Chiao JW; Goff H; Baskind P; Beer M; Ahmed T
    Bone Marrow Transplant; 1999 Nov; 24(10):1073-7. PubMed ID: 10578157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Some studies on natural killer cells in man.
    Lotzová E; McCredie KB; Maroun JA; Dicke KA; Freireich EJ
    Transplant Proc; 1979 Jun; 11(2):1390-2. PubMed ID: 314185
    [No Abstract]   [Full Text] [Related]  

  • 7. Natural killer activity of pediatric patients with acute lymphoblastic leukemia in remission.
    Inada M; Okawa H; Suzuki M; Yata J
    Jpn J Clin Oncol; 1984 Sep; 14(3):335-45. PubMed ID: 6592376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural killer activity in patients with acute myelocytic leukemia.
    Stupp Y; Rosenkovitch E; Izak G
    Isr J Med Sci; 1978 Dec; 14(12):1212-5. PubMed ID: 311767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemo-immunotherapy versus chemotherapy in acute myeloid leukemia. Preliminary results.
    Fiere D; Doillon M; Martin C; Vu Van T; Revol L
    Biomedicine; 1976 Dec; 25(9):318. PubMed ID: 1069595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of immunotherapy in acute myelogenous leukemia.
    Foon KA; Smalley RV; Riggs CW; Gale RP
    Arch Intern Med; 1983 Sep; 143(9):1726-31. PubMed ID: 6577818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
    Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
    Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoimmunotherapy of acute myelogenous leukemia with BCG-cell wall skeleton (CWS).
    Araki K; Kawano H; Kishimoto S
    Nihon Ketsueki Gakkai Zasshi; 1978 Dec; 41(6):1171-7. PubMed ID: 286492
    [No Abstract]   [Full Text] [Related]  

  • 13. Lysis of fresh leukemic blasts by interferon-activated human natural killer cells.
    Pattengale PK; Sundstrom C; Yu AL; Levine A
    Nat Immun Cell Growth Regul; 1983-1984; 3(4):165-80. PubMed ID: 6597341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia.
    Thorén FB; Romero AI; Brune M; Hellstrand K
    Expert Opin Biol Ther; 2009 Sep; 9(9):1217-23. PubMed ID: 19653866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials in vaccination with leukemia associated antigens in acute myelogenous leukemia.
    Alsabti EA; Taleb AM; Raji HM; Kalil OZ; Saleh KA
    Jpn J Exp Med; 1979 Jun; 49(3):157-68. PubMed ID: 385948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA and KIR polymorphisms affect NK-cell anti-tumor activity.
    Passweg JR; Huard B; Tiercy JM; Roosnek E
    Trends Immunol; 2007 Oct; 28(10):437-41. PubMed ID: 17825623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of natural killer cell defects in childhood acute lymphoblastic leukemia.
    Yamada S; Miyagawa Y; Komiyama A; Akabane T
    Jpn J Clin Oncol; 1984 Mar; 14(1):75-80. PubMed ID: 6608609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased natural killer cell activity in children with untreated acute leukemia.
    Nasrallah AG; Miale TD
    Cancer Res; 1983 Nov; 43(11):5580-5. PubMed ID: 6352019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer cell regeneration after transplantation with mafosfamide purged autologous bone marrow.
    Almici C; Manoni L; Carlo-Stella C; Garau D; Cottafavi L; Rizzoli V
    Bone Marrow Transplant; 1995 Jul; 16(1):95-101. PubMed ID: 7581136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of porcine natural-killer cell activity with reference to African swine-fever virus infection.
    Norley SG; Wardley RC
    Immunology; 1983 Aug; 49(4):593-7. PubMed ID: 6575959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.